Drug Profile
Difluprednate ophthalmic
Alternative Names: Durezol; SJE-2079; ST-601Latest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Senju Pharmaceutical
- Developer Alcon; Novartis; Senju Pharmaceutical; Sirion Therapeutics
- Class Analgesics; Anti-inflammatories; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Pregnadienetriols
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ocular inflammation; Ocular pain; Uveitis
- No development reported Diabetic macular oedema; Dry eyes
Most Recent Events
- 27 Aug 2019 No development reported - Phase-II for Diabetic macular oedema in Japan (Ophthalmic)
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 04 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business